Efficacy and Safety of the Third‐Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination With Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome‐Positive Acute Lymphoblastic Leukemia Patients With Refractory/Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation

Abstract excerpt

Despite significant advancements in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL), particularly the development of tyrosine kinase inhibitors (TKIs), the prognosis of refractory/relapsed (R/R) or persistent minimal residual disease (MRD)-positive Ph + ALL remains poor. For these patients, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the main...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Lymphoblastic Leukemia research
• Share to CAR-T cell therapy research